TrialLancet (London, England)2024

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.

Chiaojung Jillian Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.